



In-Vivo Xtreme II




Most advanced preclinical
Optical / X-ray imaging system

Bringing a new level of sensitivity, speed and versatility to preclinical imaging, the In-Vivo Xtreme II offers researchers greater scope to discover important biological mechanisms in disease, treatments and monitoring.

Five imaging modalities are provided as standard, allowing co-registration of molecular events with access to Bioluminescence, Multispectral VIS-NIR Fluorescence, unique Direct Radioisotopic Imaging, and Cherenkov radiation. A high speed digital X-ray with industry leading resolution and reflectance modes enhances data acquisition with anatomical features.

New features

- New camera for higher sensitivity
- Exceptionally low read noise electronics enables previously unattainable levels of detection during low-light applications
- Novel dual heating and isoflurane anaesthesia system provides optimal environment for animal imaging and welfare
- Innovative animal tray design and active evacuation system isolates users from 99.9% of harmful gas exposure
- SPF suitable animal imaging chambers
- Fully compatible with multimodal product family



Accelerate your biomedical research


Convenient and flexible

High speed switching between modalities, settings, and camera readout rates, give access to higher temporal resolution in standalone and multimodal imaging applications for dynamic imaging and biodistribution studies.


Furthermore, the option to utilize Bruker's advanced Multimodal Animal Transport Imaging Cassettes and platform specific adaptors to fuse images across Bruker's entire preclinical imaging portfolio, incorporating Optical, MRI, MPI, PET, SPECT and CT, supports custom combinations for deeper insights and quantitative analysis tuned to the investigation in question.

For a range of applications


- Tumor and stem cell tracking
- Luminescence imaging of inflammation
- Optical imaging of PET probes with either Direct Radioisotopic Imaging (DRI) or Cherenkov radiation
- Tracking and validating single or multimodal nanoparticles
- Imaging and validating new probes and biomarker
- Non-invasively image changes in signaling cascades
- Discover how genetics, small molecules and therapeutics affect biochemical pathways
- Quantify changes in bone and soft tissue phenotype
- High throughput pharmacodynamic studies




Longitudinal monitoring of PC3M-Luc cells in Foxn1 mice (1-4) compared to control (C).





Bruker Imaging Center of Excellence
Billerica, MA



Oncology studies: Multimodal X-ray, REF, FLI (red), CLI (blue), and DRI (green) in 90Y-DOTA-TATE targeting validation in mouse xenograft mCherry tumor (arrow) study. Image courtesy of Dr. R. Bergmann, Helmholtz Zentrum Dresden Rossendorf, Germany.



Inflammation and nutraceuticals: Non invasive imaging of inflammation induced myeloperoxidase activity by i.p. injection of nutraceuticals using luminol sodium salt.



In vitro Luc cell assay to test for sensitivity and linearity. Bruker Imaging Center of Excellence, Billerica, MA